The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation

European Journal of Cancer

Volumn 46, Issue 4, 2010, Pages 713-719

  Lughezzani, Giovanni ^a,b   Sun, Maxine ^a   Perrotte, Paul ^d   Jeldres, Claudio ^a   Alasker, Ahmed ^a   Isbarn, Hendrik ^a,c   Budäus, Lars ^a,c   Shariat, Shahrokh F ^a   Guazzoni, Giorgio ^b   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adrenocortical carcinoma; Prognosis; Staging system; Survival; TNM classification

Indexed keywords

ADRENAL TUMOR; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; UNIVARIATE ANALYSIS; VALIDATION STUDY;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; UNITED STATES; YOUNG ADULT;

EID: 76049095621     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.007     Document Type: Article

References (32)

1. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88 4 (2000) 711-736
2. Ng L., and Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169 1 (2003) 5-11
3. Allolio B., and Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91 6 (2006) 2027-2037
4. Dackiw A.P., Lee J.E., Gagel R.F., and Evans D.B. Adrenal cortical carcinoma. World J Surg 25 7 (2001) 914-926
5. Vassilopoulou-Sellin R., and Schultz P.N. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 92 5 (2001) 1113-1121
6. Paton B.L., Novitsky Y.W., Zerey M., et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 140 6 (2006) 914-920 [discussion 9-20]
7. Bilimoria K.Y., Shen W.T., Elaraj D., et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113 11 (2008) 3130-3136
8. Luton J.P., Cerdas S., Billaud L., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New Engl J Med 322 17 (1990) 1195-1201
9. Lee J.E., Berger D.H., el-Naggar A.K., et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118 6 (1995) 1090-1098
10. Icard P., Goudet P., Charpenay C., et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25 7 (2001) 891-897
11. Stojadinovic A., Ghossein R.A., Hoos A., et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20 4 (2002) 941-950
12. Abiven G., Coste J., Groussin L., et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91 7 (2006) 2650-2655
13. Kebebew E., Reiff E., Duh Q.Y., Clark O.H., and McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World J Surg 30 5 (2006) 872-878
14. Assie G., Antoni G., Tissier F., et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92 1 (2007) 148-154
15. De Lellis R.A., Lloyd R.V., Heitz P.U., and Eng C. Pathology and genetics of tumors of endocrine organs (2004), IARC, Lyon (France)
16. Mcfarlane D.A. Cancer of the adrenal cortex: the natural history, prognosis and treatment in the study of fifty cases. Ann R Coll Surg Engl 109 (1958) 613-618
17. Sullivan M., Boileau M., and Hodges C.V. Adrenal cortical carcinoma. J Urol 120 (1978) 660-665
18. Fassnacht M., Johanssen S., Quinkler M., et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115 2 (2009) 243-250
19. Ries LAG MD, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. , based on November 2006 SEER data submission, posted to SEER website [last accessed: January 2007]. November.
20. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 4 (1996) 361-387
21. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 3 (1988) 837-845
22. Karakiewicz P.I., Briganti A., Chun F.K., et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25 11 (2007) 1316-1322
23. Walz J., Gallina A., Saad F., et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 25 24 (2007) 3576-3581
24. Libe R., Fratticci A., and Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14 1 (2007) 13-28
25. Terzolo M., Angeli A., Fassnacht M., et al. Adjuvant mitotane treatment for adrenocortical carcinoma. New Engl J Med 356 23 (2007) 2372-2380
26. Schteingart D.E., Doherty G.M., Gauger P.G., et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12 3 (2005) 667-680
27. Abraham J., Bakke S., Rutt A., et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94 9 (2002) 2333-2343
28. Wooten M.D., and King D.K. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72 11 (1993) 3145-3155
29. Fassnacht M., Hahner S., Polat B., et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91 11 (2006) 4501-4504
30. Polat B., Fassnacht M., Pfreundner L., et al. Radiotherapy in adrenocortical carcinoma. Cancer 115 13 (2009) 2816-2823
31. Grumbach M.M., Biller B.M., Braunstein G.D., et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 138 5 (2003) 424-429
32. Reinig J.W., Doppman J.L., Dwyer A.J., Johnson A.R., and Knop R.H. Adrenal masses differentiated by MR. Radiology 158 1 (1986) 81-84